No Data
No Data
Sagimet Biosciences Is Maintained at Neutral by Goldman Sachs
Express News | Goldman Sachs Maintains Neutral on Sagimet Biosciences, Lowers Price Target to $6
Goldman Sachs Downgrades Sagimet Biosciences(SGMT.US) to Hold Rating, Cuts Target Price to $6
Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans
TD Cowen Maintains Sagimet Biosciences(SGMT.US) With Buy Rating
Express News | Sagimet Biosciences To Host Conference Call And Webcast On June 13, 2024, To Discuss Positive Data From FASCINATE-2 Phase 2b Trial Of Denifanstat In MASH Patients Presented At EASL Congress
No Data